Arbuck Sg

868 total citations · 1 hit paper
10 papers, 725 citations indexed

About

Arbuck Sg is a scholar working on Oncology, Molecular Biology and Dermatology. According to data from OpenAlex, Arbuck Sg has authored 10 papers receiving a total of 725 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 2 papers in Molecular Biology and 2 papers in Dermatology. Recurrent topics in Arbuck Sg's work include Cancer Treatment and Pharmacology (7 papers), Pituitary Gland Disorders and Treatments (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Arbuck Sg is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Pituitary Gland Disorders and Treatments (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Arbuck Sg collaborates with scholars based in United States. Arbuck Sg's co-authors include Chaudhry, Donehower Rc, Nicholas J. Petrelli, Fabio Trave, A Mittelman, John Wright, Frank M. Balis, James Drake, Richard L. Cysyk and Nanette McAtee and has published in prestigious journals such as PubMed.

In The Last Decade

Arbuck Sg

10 papers receiving 704 citations

Hit Papers

Clinical toxicities encountered with paclitaxel (Taxol). 1993 2026 2004 2015 1993 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Arbuck Sg United States 7 498 150 103 97 88 10 725
Donehower Rc United States 8 508 1.0× 196 1.3× 90 0.9× 110 1.1× 94 1.1× 10 805
Robert Stroup United States 13 360 0.7× 368 2.5× 69 0.7× 31 0.3× 36 0.4× 17 896
Anthony J. Jaslowski United States 14 898 1.8× 255 1.7× 192 1.9× 39 0.4× 159 1.8× 31 1.2k
Patricia Anne Davis United States 13 210 0.4× 178 1.2× 57 0.6× 22 0.2× 28 0.3× 34 624
Gerhard Baumgartner Austria 15 326 0.7× 242 1.6× 138 1.3× 28 0.3× 14 0.2× 44 788
Sherry Yang United States 10 305 0.6× 210 1.4× 60 0.6× 24 0.2× 72 0.8× 32 645
Mark DeMario United States 14 402 0.8× 437 2.9× 102 1.0× 42 0.4× 21 0.2× 25 809
Christiane Amendt Germany 12 294 0.6× 440 2.9× 102 1.0× 33 0.3× 15 0.2× 24 926
Rosanna Supino Italy 15 216 0.4× 326 2.2× 43 0.4× 25 0.3× 31 0.4× 23 594
Ruth A. Modzelewski United States 16 269 0.5× 427 2.8× 137 1.3× 35 0.4× 14 0.2× 21 1.1k

Countries citing papers authored by Arbuck Sg

Since Specialization
Citations

This map shows the geographic impact of Arbuck Sg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arbuck Sg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arbuck Sg more than expected).

Fields of papers citing papers by Arbuck Sg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arbuck Sg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arbuck Sg. The network helps show where Arbuck Sg may publish in the future.

Co-authorship network of co-authors of Arbuck Sg

This figure shows the co-authorship network connecting the top 25 collaborators of Arbuck Sg. A scholar is included among the top collaborators of Arbuck Sg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arbuck Sg. Arbuck Sg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Sg, Arbuck, et al.. (1999). DNA topoisomerase I poisons.. PubMed. 18. 81–124. 15 indexed citations
2.
Bd, Cheson, Phillips Ph, & Arbuck Sg. (1995). Clinical trials referral resource. Trials of topotecan.. PubMed. 9(3). 220, 224–6, 228. 1 indexed citations
3.
Sg, Arbuck. (1995). Paclitaxel: current developmental approaches of the National Cancer Institute.. PubMed. 22(6 Suppl 15). 55–63. 8 indexed citations
4.
Sg, Arbuck. (1994). Taxol (paclitaxel): future directions.. PubMed. 5 Suppl 6. S59–62. 12 indexed citations
5.
McAtee, Nanette, et al.. (1993). A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.. PubMed. 53(20). 4828–36. 19 indexed citations
6.
Bd, Cheson & Arbuck Sg. (1993). Clinical trials referral resource. Clinical trials with topotecan.. PubMed. 7(2). 49–51. 2 indexed citations
7.
Chaudhry, et al.. (1993). Clinical toxicities encountered with paclitaxel (Taxol).. PubMed. 20(4 Suppl 3). 1–15. 586 indexed citations breakdown →
8.
Sg, Arbuck. (1987). 5-FU/leucovorin: biochemical modulation that works?. PubMed. 1(2). 61–74. 21 indexed citations
9.
Trave, Fabio, et al.. (1987). Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin.. PubMed. 165–70. 57 indexed citations
10.
Sg, Arbuck, et al.. (1985). Limitations of drug sensitivity testing in soft agar for clinical management of patients with ovarian carcinoma.. PubMed. 66(1). 115–20. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026